C Diff Treatment

Study finds Clostridioides difficile infection to be associated with increased length of hospital stay and delay in scheduled chemotherapy in pediatric patients with cancer.

Click here to download the C. diff Care Guide

Patients with cancer-related diarrhea appeared 40% more likely than those without the condition to discontinue index therapy, according to retrospective study results presented during the virtual ASCO Annual Meeting.Cancer-related diarrhea also prompted earlier switches to alternate regimens and additional health care utilization, results showed.

Incidence of Clostridioides difficile infection (CDI) has been increasing in recent decades due to different factors, namely (i) extended use of broad-spectrum antibiotics, (ii) transmission within asymptomatic and susceptible patients, and (iii) unbalanced gastrointestinal microbiome and col …

Diarrhea is a common problem in nursing homes. A survey among nursing facilities in Poland was used to characterize diarrhea outbreaks, the burden caused for residents and caregivers and the employed measures. Survey results confirmed that diarrhea is a common problem in nursing homes and in most ca …

An assessment of the frontline agents show similarities infection cure and recurrence rates at 30 days.

The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

Clostridium difficile infection (CDI) is inflammation of the colon caused by a bacteria called clostridium difficile and is the most common cause of infectious diarrhea in hospitalized patients.

In this study, we report the results of the epidemiological analysis of Clostridioides difficile ribotypes (RTs) and antimicrobial susceptibility testing. Most isolates were RT027, representing 73% (84/115) of isolates. No isolates with reduced susceptibility to fidaxomicin were found; howeve …

Hospitalization for inflammatory bowel disease is common and requires coordination of care. The goals of hospitalization are to markedly improve symptoms, transition management to an outpatient regimen, and prevent complications. Initially, providers should determine the phenotype and severity of di …

The present experiments determined the effects of the narrow-spectrum antibiotic vancomycin on inflammatory pain-stimulated and pain-depressed behaviors in rats. Persistent inflammatory pain was modeled using dilute formalin (0.5%). Two weeks of oral vancomycin administered in drinking water attenua …

Antibiotic-associated diarrhea and Clostridioides difficile infection (CDI) occur frequently among adults. The pathophysiology of CDI is related to disruption of normal gut flora and risk factors include hospitalization, use of antibiotic therapy, and older age. Clinical manifestations can range fro …

C difficile and sepsis infections can be especially difficult to treat.

Fidaxomicin, and to a lesser extent vancomycin, reduces C. difficile shedding and contamination of the hospital environment relative to metronidazole. Treatment choice may play a role in reducing healthcare-associated C. difficile transmission.

A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.

It’s possible that C diff could be a marker for frailty in geriatric patients.

Revised clinical practice guidelines for Clostridioides difficile that were published in February 2018 led to immediate, significant increases in oral vancomycin and fidaxomicin use in the United States, as well as a significant decrease in oral metronidazole use, according to findings published in Clinical Infectious Diseases. “Shortly before this study, the Infectious Diseases Society of

In results from a phase 2 trial show 7.5gm of DAV132 administered three times daily demonstrated protection against antibiotic-induced disruption of intestinal microbiota.

Implications regarding how to properly treat patients with C. difficile infections based on data that have emerged since clinical practice guidelines were last updated.

Important factors to consider when selecting an appropriate therapy to treat C. difficile.

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.  

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.